Clik here to view.
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in...
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021,...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase 1 clinical study to evaluate the pharmacokinetics,...
View ArticleClik here to view.
EdiGene Enters Strategic R＆D Collaboration with Haihe Laboratory of Cell...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
Ranok Therapeutics Announces U.S. FDA Clearance to Proceed With Its...
BOSTON & HANGZHOU, China Ranok Therapeutics, a biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious...
View ArticleClik here to view.
Flatiron Health Announces RWD Partnership With Japan’s NCCHE
NEW YORK Flatiron HealthⓇ today announced a partnership with Japan’s National Cancer Center Hospital East (NCCHE) to build a real-world database of patients with gastro-intestinal cancers. “Insights...
View ArticleClik here to view.
BeiGene Announces Acceptance of Supplemental New Drug Application in China...
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today...
View ArticleClik here to view.
モンロールがGMPグレード無担体Lu-177の製造技術をキュリウムにライセンスする契約を締結
イスタンブール （ビジネスワイヤ） — エジザージュバシュ・モンロール・ニュークリア・プロダクツ（モンロール）は本日、キュリウム・ネザーランド（キュリウム）と契約を締結し、モンロールのGMPグレード医療用放射性同位元素である無担体177Lu (n.c.a....
View ArticleClik here to view.
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve...
View ArticleClik here to view.
ZAPサージカルが日本の新幹線駅に先駆的な放射線手術プラットフォームを設置と発表
米カリフォルニア州サンカルロス （ビジネスワイヤ） — – ZAPサージカル・システムズは本日、当社のZAP-X®ジャイロスコープ・ラジオサージェリー（Gyroscopic...
View ArticleClik here to view.
ZAP Surgical Announces Installation of its Pioneering Radiosurgery Platform...
SAN CARLOS, Calif. ZAP Surgical Systems, Inc. today announced installation of its first ZAP-X® Gyroscopic Radiosurgery® platform in Japan. Using a new vault-free design that typically eliminates the...
View ArticleClik here to view.
Clik here to view.
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of...
View ArticleClik here to view.
New Study Validates Novel Markers for Detecting Microsatellite Instability in...
MADISON, Wis. Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI)...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Enters Into Definitive Agreement to Acquire German...
FRANKFURT, Germany & HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”)...
View ArticleClik here to view.
ドクター・レディーズ・ラボラトリーズがドイツの医療用大麻企業ニンバス・ヘルスを買収するための正式契約を締結
独フランクフルト & 印ハイデラバード （ビジネスワイヤ） — ドクター・レディーズ・ラボラトリーズ（BSE: 500124、NSE: DRREDDY、NYSE: RDY、NSEIFSC: DRREDDY、子会社と合わせて「ドクター・レディーズ」と表記）は本日、Nimbus Health...
View ArticleClik here to view.
Monrol签署协议将GMP级镥-177 n.c.a生产技术授权给Curium
伊斯坦布尔 (美国商业资讯)– Eczacıbaşı-Monrol Nuclear Products Co. (Monrol)今天宣布已就其GMP级医用放射性同位素无载体添加177镥（n.c.a.177镥）尖端生产技术LuMagic®与Curium Netherlands B.V (Curium)签署授权协议。Monrol通过该协议将相关设备和物料转让给Curium。...
View ArticleClik here to view.
CANbridge Reports Positive Top-Line CAN106 Phase 1 Data
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc. (“CANbridge,” stock code 1228.HK), a China-based global biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel...
SEONGNAM-SI, South Korea Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug...
View ArticleClik here to view.
武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda, TOKYO:4502/NYSE:TAK)今天公布了强劲的2021财年第三季度业绩（截至2021年12月31日的期间），这一业绩得益于其14个全球品牌稳健的营收增长。基于强劲的第三季度业绩和业务势头，武田更新了整个财年营收、列报经营利润和核心经营利润、列报每股收益和核心每股收益以及自由现金流的预测。...
View Article